Published in Diabetes Ther on January 18, 2011
G protein-coupled receptors as targets for anti-diabetic therapeutics. Nat Rev Drug Discov (2016) 0.83
Oral delivery of glucagon-like peptide-1 and analogs: alternatives for diabetes control? J Diabetes Sci Technol (2012) 0.79
Comparative Assessment of Lixisenatide, Exenatide, and Liraglutide Pen Devices: A Pilot User-Based Study. J Diabetes Sci Technol (2014) 0.78
Effects of exenatide in a morbidly obese patient with type 2 diabetes. Diabetes Ther (2014) 0.78
GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. Obesity (Silver Spring) (2015) 0.78
Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists. Clin Diabetes (2014) 0.75
Forum for Injection Technique and Therapy Expert Recommendations, India: The Indian Recommendations for Best Practice in Insulin Injection Technique, 2017. Indian J Endocrinol Metab (2017) 0.75
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet (2009) 9.32
The biology of incretin hormones. Cell Metab (2006) 8.92
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care (2009) 4.79
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin (2008) 3.58
PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION. J Clin Endocrinol Metab (1964) 3.29
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab (2001) 3.09
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia (2002) 2.97
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care (2007) 2.92
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care (2009) 2.75
Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology (2004) 2.65
Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology (2010) 2.33
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin (2008) 2.24
The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol (2008) 2.13
Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med (2008) 2.04
Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab (2005) 2.04
Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy. N Engl J Med (2010) 1.91
Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care (2003) 1.66
Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab (2000) 1.56
Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care (2010) 1.33
The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes (2003) 1.30
Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. Rev Diabet Stud (2008) 1.19
GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet. Am J Physiol Endocrinol Metab (2010) 0.97
Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide? Curr Diab Rep (2010) 0.90
Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitus. Mayo Clin Proc (2010) 0.89
Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation. Acta Diabetol (1993) 0.82
The role of incretins in cardiovascular control. Curr Hypertens Rep (2009) 0.80
Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study. Diabetes Care (2011) 4.30
Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol Ther (2008) 3.82
Performance variability of seven commonly used self-monitoring of blood glucose systems: clinical considerations for patients and providers. J Diabetes Sci Technol (2013) 2.58
Use of an insulin bolus advisor improves glycemic control in multiple daily insulin injection (MDI) therapy patients with suboptimal glycemic control: first results from the ABACUS trial. Diabetes Care (2013) 1.60
A structured self-monitoring of blood glucose approach in type 2 diabetes encourages more frequent, intensive, and effective physician interventions: results from the STeP study. Diabetes Technol Ther (2011) 1.38
Primary care physicians identify and act upon glycemic abnormalities found in structured, episodic blood glucose monitoring data from non-insulin-treated type 2 diabetes. Diabetes Technol Ther (2009) 1.33
Self-monitoring of blood glucose: benefits and utilization. Diabetes Educ (2006) 1.13
A single-center, open, comparative study of the effect of using self-monitoring of blood glucose to guide therapy on preclinical atherosclerotic markers in type 2 diabetic subjects. J Diabetes Sci Technol (2010) 0.98
Use of an automated decision support tool optimizes clinicians' ability to interpret and appropriately respond to structured self-monitoring of blood glucose data. Diabetes Care (2012) 0.95
The impact of structured blood glucose testing on attitudes toward self-management among poorly controlled, insulin-naïve patients with type 2 diabetes. Diabetes Res Clin Pract (2012) 0.93
Is hyperglycemia a causal factor in cardiovascular disease? Does proving this relationship really matter? Yes. Diabetes Care (2009) 0.87
Review of clinical trials: update on oral insulin spray formulation. Diabetes Obes Metab (2009) 0.87
Automated bolus advisor control and usability study (ABACUS): does use of an insulin bolus advisor improve glycaemic control in patients failing multiple daily insulin injection (MDI) therapy? [NCT01460446]. BMC Fam Pract (2012) 0.86
Changes in A1C levels are significantly associated with changes in levels of the cardiovascular risk biomarker hs-CRP: results from the SteP study. Diabetes Care (2013) 0.86
Use of an insulin bolus advisor facilitates earlier and more frequent changes in insulin therapy parameters in suboptimally controlled patients with diabetes treated with multiple daily insulin injection therapy: results of the ABACUS trial. Diabetes Technol Ther (2014) 0.84
Internet resources to improve health care for patients with diabetes. Endocr Pract (2006) 0.81
Type 2 diabetes: an expanded view of pathophysiology and therapy. Postgrad Med (2010) 0.80
2-Year follow-up to STeP trial shows sustainability of structured self-monitoring of blood glucose utilization: results from the STeP practice logistics and usability survey (STeP PLUS). Diabetes Technol Ther (2013) 0.78
Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2007) 0.77
Self-monitoring of blood glucose cannot compensate for ineffective diabetes management. Am J Med (2005) 0.77
Use of automated bolus advisors may improve adherence to multiple daily insulin injection therapy. J Diabetes Sci Technol (2012) 0.75
Biosimilar insulins are coming: what they are, what you need to know. Curr Med Res Opin (2014) 0.75
Optimizing insulin pump therapy: the potential advantages of using a structured diabetes management program. Curr Med Res Opin (2015) 0.75